PT  - JOURNAL ARTICLE
AU  - TAMIYA, MOTOHIRO
AU  - TAMIYA, AKIHIRO
AU  - NAKAO, KEIKO
AU  - ASAMI, KAZUHIRO
AU  - OKISHIO, KYOICHI
AU  - SATOMU, MORITA
AU  - SHIROYAMA, TAKAYUKI
AU  - MORISHITA, NAOKO
AU  - SUZUKI, HIDEKAZU
AU  - SASADA, SHINJI
AU  - OKAMOTO, NORIO
AU  - OKISHIO, KYOICHI
AU  - KAWAGUCHI, TOMOYA
AU  - KOBAYASHI, MASASHI
AU  - ATAGI, SHINJI
AU  - HIRASHIMA, TOMONORI
AU  - KAWASE, ICHIRO
TI  - Efficacy of Carboplatin and Paclitaxel with Bevacizumab as Salvage Chemotherapy for Non-small Cell Lung Cancer after Failure of Platinum-doublet Chemotherapy
DP  - 2012 Aug 01
TA  - Anticancer Research
PG  - 3553--3557
VI  - 32
IP  - 8
4099  - http://ar.iiarjournals.org/content/32/8/3553.short
4100  - http://ar.iiarjournals.org/content/32/8/3553.full
SO  - Anticancer Res2012 Aug 01; 32
AB  - Background: Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported. Patient and Methods: Medical records of patients with non-squamous NSCLC who received CP plus BEV between November 2009 and September 2011 and experienced progression after at least one platinum-based-chemotherapy regimen, were examined in this retrospective study. Results: Twenty-one patients were eligible for this study. The median number of prior chemotherapy regimens was 3 (range, 2 to 9). The median number of cycles of CP with BEV was 4 (range, 1 to 6). Seven patients underwent BEV maintenance therapy, and the median number of cycles of BEV maintenance was 8 (range, 2 to 13). Toxicity levels were acceptable. The overall median survival time was not reached and one-year survival rate was 54.95%. The overall progression-free survival was 6.1 months (95% confidence interval, 4.4-9.3 months). Conclusion: CP with BEV was effective and feasible as a salvage chemotherapy after failure of platinum-based chemotherapy for patients with non-squamous NSCLC.